In 2024, Insulet shared results from its landmark SECURE-T2D pivotal trial, demonstrating improved glycemic outcomes with Omnipod 5 compared with prior insulin injection or pump therapy in adults with ...

Spending more time in glucose range could help reduce adverse pregnancy outcomes, but available closed-loop insulin delivery systems are not customized to pregnancy-specific needs. In a randomized ...

Indicated for people with Type 2 diabetes, the system would be Insulet’s first fully automated device for insulin delivery.

Compared with standard care, a closed-loop insulin delivery system increased the time spent within the pregnancy-specific glucose target range between 16 and 34 weeks 6 days ’ gestation among pregnant ...